专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US09156827B2 Anticancer agent 有权
标题翻译：抗癌剂
公开(公告)号：US09156827B2
公开(公告)日：2015-10-13
申请号：US13643002
申请日：2011-04-28
申请人： Tetsuo Nagano , Takayoshi Okabe , Hirotatsu Kojima , Nae Saito , Hirofumi Nakano , Masanao Abe , Akiko Tanaka , Teruki Honma , Shigeyuki Yokoyama , Keiko Tsuganezawa , Hitomi Yuki
发明人： Tetsuo Nagano , Takayoshi Okabe , Hirotatsu Kojima , Nae Saito , Hirofumi Nakano , Masanao Abe , Akiko Tanaka , Teruki Honma , Shigeyuki Yokoyama , Keiko Tsuganezawa , Hitomi Yuki
IPC分类号： C07D405/14 , A61K31/36 , A61K31/454 , A61K31/496 , A61K31/5377 , C07D405/06 , C07D493/04 , C07D413/14 , C07D417/14 , C07D471/04
CPC分类号： C07D405/14 , A61K31/36 , A61K31/454 , A61K31/496 , A61K31/5377 , C07D405/06 , C07D413/14 , C07D417/14 , C07D471/04 , C07D493/04
摘要： An anticancer agent comprising a compound represented by the formula (I) [R1 represents hydrogen atom, hydroxyl group, a C1-6 alkoxy group and the like; R2 and R3 represents hydrogen atom, a halogen atom, a C1-6 alkyl group and the like; R4 represents hydrogen atom, a C1-6 alkyl group, a C1-6 alkylsulfonyl group and the like; R5 represents hydrogen atom or a substituent; represents a single bond or a double bond; R6 and R7 represents hydrogen atom, a C1-6 alkyl group and the like; R8 represents hydrogen atom, a C1-6 alkyl group and the like; A represents —O—, —S—, or —CH2—; D represents —C═ or —N═; X represents methylene group, —O—, or —CO—; Q represents —N═ or —C(R8)═; and Y represents a heterocyclic group or amino group], which shows a superior inhibitory activity against pim-1 kinase.
摘要翻译：包含由式（I）表示的化合物[R 1表示氢原子，羟基，C 1-6烷氧基等]的抗癌剂， R2和R3表示氢原子，卤素原子，C1-6烷基等; R4表示氢原子，C1-6烷基，C1-6烷基磺酰基等; R5代表氢原子或取代基; 代表单键或双键; R6和R7表示氢原子，C1-6烷基等; R8表示氢原子，C1-6烷基等; A表示-O - ， - S-或-CH 2 - ; D表示-C≡或-N =; X表示亚甲基，-O-或-CO-; Q表示-N =或-C（R 8）= Y表示杂环基或氨基]，这表现出对pim-1激酶的优异抑制活性。

2. 发明申请

US20130102776A1 ANTICANCER AGENT 有权
标题翻译： ANTICANCER代理
公开(公告)号：US20130102776A1
公开(公告)日：2013-04-25
申请号：US13643002
申请日：2011-04-28
申请人： Tetsuo Nagano , Takayoshi Okabe , Hirotatsu Kojima , Nae Saito , Hirofumi Nakano , Masanao Abe , Akiko Tanaka , Teruki Honma , Shigeyuki Yokoyama , Keiko Tsuganezawa , Hitomi Yuki
发明人： Tetsuo Nagano , Takayoshi Okabe , Hirotatsu Kojima , Nae Saito , Hirofumi Nakano , Masanao Abe , Akiko Tanaka , Teruki Honma , Shigeyuki Yokoyama , Keiko Tsuganezawa , Hitomi Yuki
IPC分类号： C07D405/14 , C07D493/04 , C07D413/14 , C07D471/04 , C07D417/14 , C07D405/06
CPC分类号： C07D405/14 , A61K31/36 , A61K31/454 , A61K31/496 , A61K31/5377 , C07D405/06 , C07D413/14 , C07D417/14 , C07D471/04 , C07D493/04
摘要： An anticancer agent comprising a compound represented by the formula (I) [R1 represents hydrogen atom, hydroxyl group, a C1-6 alkoxy group and the like; R2 and R3 represents hydrogen atom, a halogen atom, a C1-6 alkyl group and the like; R4 represents hydrogen atom, a C1-6 alkyl group, a C1-6 alkylsulfonyl group and the like; R5 represents hydrogen atom or a substituent; represents a single bond or a double bond; R6 and R7 represents hydrogen atom, a C1-6 alkyl group and the like; R8 represents hydrogen atom, a C1-6 alkyl group and the like; A represents —O—, —S—, or —CH2—; D represents —C═ or —N═; X represents methylene group, —O—, or —CO—; Q represents —N═ or —C(R8)═; and Y represents a heterocyclic group or amino group], which shows a superior inhibitory activity against pim-1 kinase.
摘要翻译：包含由式（I）表示的化合物[R 1表示氢原子，羟基，C 1-6烷氧基等]的抗癌剂， R2和R3表示氢原子，卤素原子，C1-6烷基等; R4表示氢原子，C1-6烷基，C1-6烷基磺酰基等; R5代表氢原子或取代基; 代表单键或双键; R6和R7表示氢原子，C1-6烷基等; R8表示氢原子，C1-6烷基等; A表示-O - ， - S-或-CH 2 - ; D表示-C =或-N =; X表示亚甲基，-O-或-CO-; Q表示-N =或-C（R8）=; Y表示杂环基或氨基]，这表现出对pim-1激酶的优异抑制活性。

3. 发明授权

US06838548B1 Artiodactyl epimorphine 失效
标题翻译：偶氮酰基异丙肾上腺素
公开(公告)号：US06838548B1
公开(公告)日：2005-01-04
申请号：US09744989
申请日：1999-08-20
申请人： Keiko Tsuganezawa
发明人： Keiko Tsuganezawa
IPC分类号： C12N15/09 , A61K38/00 , C07K14/47 , C07K14/475 , C07K16/18 , C07K14/75 , C07H21/04
CPC分类号： C07K14/475 , A61K38/00
摘要： An epimorphin protein having action to induce differentiation of milk protein-producing cells into a branched luminal structure in Artiodactyls including cows and sheep and comprising an amino acid sequence set forth in SEQ ID NO: 1 in the Sequence Listing; and a gene encoding said protein are provided. The epimorphin protein of the present invention can be used as a medicament for Artiodactyls or an agent for modifying animal properties. For example, the protein acts to enlarge the mammary gland of cows or sheep to prevent the gland from clogging, thereby a yield of a desired protein secreted in the milk of the animal is increased.

4. 发明授权

US06335175B1 Anti-human pre-B cell receptor antibody 失效
标题翻译：抗人B细胞受体抗体
公开(公告)号：US06335175B1
公开(公告)日：2002-01-01
申请号：US09494252
申请日：2000-01-31
申请人： Keiko Tsuganezawa , Hajime Karasuyama
发明人： Keiko Tsuganezawa , Hajime Karasuyama
IPC分类号： G01N33574
CPC分类号： G01N33/56972 , C07K16/28
摘要： The present invention provides an antibody which recognizes a human pre-B cell receptor and does not recognize a human pro-B cell. The invention also provides an antibody which reacts with a VpreB molecule, one of the constituents of an SL chain of a human pre-B cell receptor expressed on the membrane surface of a human pre-B cell, or a VpreB molecule expressed within a human pro-B cell, but does not react with a &lgr;5 molecule of the surrogate light chain, and whose reactivity is such that a human pre-B cell or a human pro-B cell reacted with the antibody can be detected microscopically. The invention further provides a method for diagnosing which differentiation stage of B cells acute lymphoblastic leukemia in childhood stems from, by using an antibody which recognizes a human pre-B cell receptor, and does not recognize a human pro-B cell, an antibody which recognizes a VpreB molecule of a surrogate light chain constituting a human pre-B cell receptor, an antibody which recognizes a &lgr;5 molecule of the surrogate light chain constituting a human pre-B cell receptor, and an antibody which recognizes a B cell.
摘要翻译：本发明提供了识别人前B细胞受体并且不识别人前B细胞的抗体。本发明还提供了一种与VpreB分子反应的抗体，VpreB分子是在人前B细胞的膜表面上表达的人前B细胞受体的SL链的成分之一或在人中表达的VpreB分子 pro-B细胞，但不与替代轻链的lambd5分子反应，并且其反应性使得可以显微检测与抗体反应的人前B细胞或人类前体B细胞。本发明还提供了一种通过使用识别人前B细胞受体的抗体并且不识别人前B细胞来诊断儿童B细胞急性淋巴细胞白血病的哪个分化阶段的方法，识别构成人前B细胞受体的替代轻链的VpreB分子，识别构成人前B细胞受体的替代轻链的羔羊5分子的抗体和识别B细胞的抗体。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式